Life Sciences Co. Exceeds Expectations in Q3/22

Research Report
  ()
During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.

Blockchain Co. Signs Agreement With Insurance Co.

  ()
Global Compliance Applications Corp. signs an agreement with a South African insurance company to get into that country’s expanding cannabis industry.

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

Research Report
  ()
The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.

Pharma Co. Won't See Bump in Sales From New COVID Drug

Research Report
  ()
The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

  ()
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

  ()
With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.

Clean Nuclear Med Tech With Quantum Blue Sky

Contributed Opinion
  ()
With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.

Expert Investing Ideas

"AGN is rated a Buy again here."

–Clive Maund, CliveMaund.com


"AGN is rated an immediate Strong Buy."

–Clive Maund, CliveMaund.com


"This is a good time to buy PMN stock."

–Clive Maund, CliveMaund.com


"AGN is rated Buy again here."

–Clive Maund, CliveMaund.com


"AGN has the capacity to make really big moves."

–Clive Maund, CliveMaund.com


"It would be logical for AGN to develop ifenprodil for two indications."

–Dr. André Uddin, Research Capital Corporation


"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

–Dr. André Uddin, Research Capital Corporation


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Nine Stocks Expert Says Should Pique Your Interest

Contributed Opinion
  ()
Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on.

Medical Device Co.'s Q2/22 Results Better Than Expected

Research Report
  ()
Along with improving its numbers during the quarter, this firm sold its first ultrasound ablation machines in North America, noted a Research Capital Corp. report.

Telemedicine Co. Surges on Revenue News

  ()
As internet-enabled health care becomes more accepted in the wake of the pandemic, telemedicine company Reliq Health Technologies Inc. is seeing its revenue soar.